SCHEMBL20166479

SCHEMBL20166479

Cc1ccc(N2CCN(CCC3CC4(CCN(C(=O)OC(C)(C)C)CC4)C(=O)O3)CC2)c(N2CCOCC2)c1

nearest known ligand 0.70

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 20/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31399312 1.00 HTR7 (0.70) HTR7
SCHEMBL22723071 0.91 HTR7 (0.70) HTR7
SCHEMBL20179539 0.91 HTR7 (0.70) HTR7
SCHEMBL31530586 0.91 HTR7 (0.70) HTR7
SCHEMBL20179540 0.91 HTR7 (0.70) HTR7
SCHEMBL31530592 0.91 HTR7 (0.70) HTR7
SCHEMBL22723098 0.89 HTR7 (0.76) HTR7
SCHEMBL20181022 0.89 HTR7 (0.72) HTR7
SCHEMBL31680071 0.89 HTR7 (0.72) HTR7
SCHEMBL31680072 0.89 HTR7 (0.72) HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4684837-A1 NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE Temple University of the Commonwealth System of Higher Education (US) 2026-01-28 EP disclosed
US-20250282790-A1 NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE PRAEVENTIX, LLC 2025-09-11 US disclosed
EP-3541790-B1 3-(2-(4-PHENYLPIPERAZIN-1-YL)ETHYL)-2-OXA-8-AZASPIRO[4.5]DECAN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS 5-HYDROXYTRYPTAMINE RECEPTOR 7 (5-HT7) MODULATORS FOR TREATING E.G. INFLAMMATORY BOWEL DISEASE, CIRCADIAN RHYTHM DISORDER OR DEPRESSION UNIV TEMPLE (US) 2025-09-03 EP disclosed
US-12338247-B2 Modulators of the 5-hydroxytryptamine receptor 7 and their method of use TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2025-06-24 US disclosed
CN-119977980-A Novel modulators of 5-hydroxytryptamine receptor 7 and methods of use thereof 英联邦高等教育系统坦普尔大学 2025-05-13 CN disclosed
CN-110177776-B Novel modulators of 5-hydroxytryptamine receptor 7 and methods of use thereof 英联邦高等教育系统坦普尔大学 2025-02-28 CN disclosed
US-20230112888-A1 NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE PRAEVENTIX, LLC 2023-04-13 US disclosed
US-11319327-B2 Modulators of the 5-hydroxytryptamine receptor 7 and their method of use Temple University—Of the Commonwealth System of Higher Education (US) 2022-05-03 US disclosed
US-11319327-B2 Modulators of the 5-hydroxytryptamine receptor 7 and their method of use Temple University—Of the Commonwealth System of Higher Education (US) 2022-05-03 US disclosed
US-20210238189-A1 NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE PRAEVENTIX, LLC 2021-08-05 US disclosed
US-20210238189-A1 NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE PRAEVENTIX, LLC 2021-08-05 US disclosed
US-10858368-B2 Modulators of the 5-hydroxytryptamine receptor 7 and their method of use Temple University—Of the Commonwealth System of Higher Education (US) 2020-12-08 US disclosed
US-10858368-B2 Modulators of the 5-hydroxytryptamine receptor 7 and their method of use Temple University—Of the Commonwealth System of Higher Education (US) 2020-12-08 US disclosed
EP-3541790-A1 NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE Temple University - Of The Commonwealth System of Higher Education (US) 2019-09-25 EP disclosed
WO-2018093818-A1 NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2018-05-24 WO disclosed
WO-2018093818-A1 NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2018-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250282790-A1 NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE HTR7, HTR5A, HTR6 HTR7 1/4885
US-10858368-B2 Modulators of the 5-hydroxytryptamine receptor 7 and their method of use HTR7, HTR6, HTR5A HTR7 1/4885
US-20230112888-A1 NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE HTR7, HTR5A, HTR6 HTR7 1/4885
US-11319327-B2 Modulators of the 5-hydroxytryptamine receptor 7 and their method of use HTR7, HTR6, HTR5A HTR7 1/4885
US-12338247-B2 Modulators of the 5-hydroxytryptamine receptor 7 and their method of use HTR7, HTR6, HTR5A HTR7 1/4885
US-20210238189-A1 NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE HTR7, HTR5A, HTR6 HTR7 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.